Trial to control the formation of endolymphatic hydrops from the viewpoint of the water homeostasis of the inner ear

IF 1.6 4区医学 Q2 OTORHINOLARYNGOLOGY

Auris Nasus Larynx Pub Date : 2025-02-01 DOI:10.1016/j.anl.2025.01.001

Taizo Takeda , Setsuko Takeda , Akinobu Kakigi

{"title":"Trial to control the formation of endolymphatic hydrops from the viewpoint of the water homeostasis of the inner ear","authors":"Taizo Takeda , Setsuko Takeda , Akinobu Kakigi","doi":"10.1016/j.anl.2025.01.001","DOIUrl":null,"url":null,"abstract":"<div><div>Endolymphatic hydrops, which is one of the pathologic features of Ménière's disease, has been experimentally and clinically confirmed to be influenced by the blood circulation of vasopressin (VP). It is widely acknowledged that VP plays a pivotal role in regulating water homeostasis. It should also be noted that VP is susceptible to a number of external factors, including changes in the environment, dehydration, and fluctuations in atmospheric pressure. Furthermore, VP is a key regulator of the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is a significant neuroendocrine system that plays a role in regulating responses to emotional and physical stress, as well as the sleep/wake cycle (circadian rhythm). It seems that VP is changeable via the HPA axis. It may be beneficial to consider pharmacological normalization of VP as a potential approach to controlling Ménière's disease. Nevertheless, measuring 8-Arg-vasopressin (AVP), the most prevalent variant of VP, poses certain challenges for a number of reasons. Copeptin is co-released with AVP, is relatively stable in the posterior pituitary as well as in blood plasma, and is increasingly being used as an AVP surrogate in clinical diagnostics. It is thought that the use of copeptin as a marker for AVP may help to clarify the clinical features of Ménière's disease.</div><div>In this review, we will consider trials to control the formation of endolymphatic hydrops from the viewpoint of the vasopressin-aquaporin 2 system. Furthermore, we will explore reports on clinical treatment, pharmacological agents, and future prospects.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"52 2","pages":"Pages 137-140"},"PeriodicalIF":1.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Auris Nasus Larynx","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0385814625000033","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Endolymphatic hydrops, which is one of the pathologic features of Ménière's disease, has been experimentally and clinically confirmed to be influenced by the blood circulation of vasopressin (VP). It is widely acknowledged that VP plays a pivotal role in regulating water homeostasis. It should also be noted that VP is susceptible to a number of external factors, including changes in the environment, dehydration, and fluctuations in atmospheric pressure. Furthermore, VP is a key regulator of the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is a significant neuroendocrine system that plays a role in regulating responses to emotional and physical stress, as well as the sleep/wake cycle (circadian rhythm). It seems that VP is changeable via the HPA axis. It may be beneficial to consider pharmacological normalization of VP as a potential approach to controlling Ménière's disease. Nevertheless, measuring 8-Arg-vasopressin (AVP), the most prevalent variant of VP, poses certain challenges for a number of reasons. Copeptin is co-released with AVP, is relatively stable in the posterior pituitary as well as in blood plasma, and is increasingly being used as an AVP surrogate in clinical diagnostics. It is thought that the use of copeptin as a marker for AVP may help to clarify the clinical features of Ménière's disease.

In this review, we will consider trials to control the formation of endolymphatic hydrops from the viewpoint of the vasopressin-aquaporin 2 system. Furthermore, we will explore reports on clinical treatment, pharmacological agents, and future prospects.

查看原文本刊更多论文

从内耳水平衡的角度探讨内耳淋巴水肿的形成。

血管加压素（VP）的血液循环影响了内淋巴积液，是mims病的病理特征之一。人们普遍认为VP在调节水稳态中起着关键作用。还应该指出的是，VP易受许多外部因素的影响，包括环境的变化、脱水和大气压的波动。此外，VP是下丘脑-垂体-肾上腺（HPA）轴的关键调节因子。下丘脑轴是一个重要的神经内分泌系统，在调节对情绪和身体压力的反应以及睡眠/觉醒周期（昼夜节律）中发挥作用。VP似乎可以通过下丘脑轴改变。这可能是有益的考虑药理学正常化的VP作为一个潜在的途径，以控制membrolizumab病。然而，测量8- arg -抗利尿激素（AVP），最普遍的VP变体，由于一些原因，提出了某些挑战。Copeptin与AVP共释放，在垂体后叶和血浆中相对稳定，越来越多地被用作AVP的替代品用于临床诊断。我们认为使用copeptin作为AVP的标记物可能有助于阐明membroini病的临床特征。在这篇综述中，我们将从加压素-水通道蛋白2系统的角度考虑控制内淋巴水肿形成的试验。此外，我们将探讨临床治疗，药理药物和未来展望的报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Auris Nasus Larynx 医学-耳鼻喉科学

CiteScore

3.40

自引率

5.90%

发文量

169

审稿时长

30 days

期刊介绍： The international journal Auris Nasus Larynx provides the opportunity for rapid, carefully reviewed publications concerning the fundamental and clinical aspects of otorhinolaryngology and related fields. This includes otology, neurotology, bronchoesophagology, laryngology, rhinology, allergology, head and neck medicine and oncologic surgery, maxillofacial and plastic surgery, audiology, speech science. Original papers, short communications and original case reports can be submitted. Reviews on recent developments are invited regularly and Letters to the Editor commenting on papers or any aspect of Auris Nasus Larynx are welcomed. Founded in 1973 and previously published by the Society for Promotion of International Otorhinolaryngology, the journal is now the official English-language journal of the Oto-Rhino-Laryngological Society of Japan, Inc. The aim of its new international Editorial Board is to make Auris Nasus Larynx an international forum for high quality research and clinical sciences.